Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Suvratoxumab - MedImmune

Drug Profile

Suvratoxumab - MedImmune

Alternative Names: MEDI-4893

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosynexus; GlaxoSmithKline; Regeneron Pharmaceuticals
  • Developer MedImmune
  • Class Anti-infectives; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nosocomial pneumonia

Most Recent Events

  • 02 Oct 2019 Pharmacokinetics data from a clinical study including patients from the phase I and phase II trial in Nosocomial pneumonia presented at the IDWeek (IDW-2019)
  • 02 Oct 2019 Updated pharmacokinetics data from the phase II SAATELLITE trial in Nosocomial pneumonia presented at the IDWeek (IDW-2019)
  • 02 Oct 2018 MedImmune completes the SAATELLITE phase II trial in Nosocomial pneumonia (Prevention) in Portugal, United Kingdom, Belgium, Czech Republic, France, Germany, Greece, Hungary, Spain and Switzerland (IV) (NCT02296320)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top